Benzinga
Benzinga
Benzinga
mercoledì, settembre 30

Protagonist Therapeutics Inc

PTGXNASDAQ
Trade with Public
Trade with Public
$140.97
-1.47-1.03%
In chiusura: Sep 29, 5:00 PM EST
$140.97
N/A
Post-mercato: 4:00 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Protagonist Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Protagonist Therapeutics (PTGX).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

3S.Buy
14Buy
Consensus RatingBuy# Analysts17Avg. Consensus PT$129Upside to Avg. PT-8.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 1, 2026BarclaysEtzer DaroutPT RaiseOverweight$153→$180
Sep 1, 2026BMO CapitalEtzer DaroutPT RaiseOutperform$178→$190
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180

Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $153 to $180.
Benzinga Newsdesk

Apple To $303? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Cantor Fitzgerald raised
Avi Kapoor

PRO
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $178 to $190.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $167 to $170.
Benzinga Newsdesk

PRO
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178

BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $178.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $145 to $170.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved